While clinically significant interactions with subcutaneous GLP-1 receptor agonists are generally limited, your doctor may wish to review medications with a narrow therapeutic index on a case-by-case basis
Real-world use beyond this timeframe is becoming more common, with many individuals maintaining therapy for years
This level of efficacy approaches that of sleeve gastrectomy (25-30% at 1 year) and represents a transformative advance in non-surgical obesity treatment
While the clinical relevance of these findings in a population largely free from kidney disease remains uncertain, the reductions in albuminuria, blood pressure, and the favourable safety profile support further investigation of retatrutides potential kidney-protective effects in high-risk populations
Finally, phentermine can serve as a test of medication-assisted weight loss
Visible results often appear within a month, especially when Tirzepatide is combined with supportive care